Purpose
Polycyclic aromatic hydrocarbons (PAH)-DNA adducts have been associated with breast cancer incidence. Aberrant changes in DNA methylation may be an early event in carcinogenesis. However, possible relations between PAH-DNA adducts, methylation and breast cancer are unknown. The objectives of this study were to (1) assess associations between PAH-DNA adducts and breast cancer, stratified by DNA methylation markers; and, (2) to examine interactions between adducts and DNA methylation in association with breast cancer and tumor subtype.
Methods
In a population-based case-control study, promoter methylation of 13 breast cancer-related genes was measured in tumor tissue (n=765-851 cases). Blood DNA from breast cancer cases (n=873) and controls (n=941) was used to assess PAH-DNA adducts and global methylation. Logistic regression was used to estimate adjusted odds ratios (ORs) and 95% confidence intervals (CI); and the ratio of the OR (ROR) was used to assess heterogeneity.
Results
Women with detectable PAH-DNA adducts and methylated RARβ (ROR=2.69, 95%CI 1.02-7.12; p for interaction=0.03) or APC (ROR=1.76, 95%CI 0.87-3.58; p for interaction=0.09) genes were more likely to have hormone receptor-positive tumors than other subtypes. Interactions with other methylation markers were not apparent (p≥0.10). The association between adducts and breast cancer did not vary by methylation status of the tumor nor did adducts associate with global methylation in the controls.
Conclusions
Gene-specific methylation of RARβ, and perhaps APC, may interact with PAHDNA adducts to increase risk of hormone receptor-positive breast cancer. There was little evidence that adducts were associated with or interacted with other methylation markers of interest.